n=142 bleeding episodes
ACHIEVE CONTROL WHEN BLEEDS OCCUR
Studies show Rebinyn® provided effective control in 95% of bleeding episodes; 98% of bleeds were treated with 1-2 infusions.1
ACHIEVE CONTROL WHEN BLEEDS OCCUR
Studies show Rebinyn® provided effective control in 95% of bleeding episodes; 98% of bleeds were treated with 1-2 infusions.1
REBINYN® IS EFFECTIVE WHEN BLEEDS OCCUR IN ADULTS AND ADOLESCENTS
Bleeds treated with 1-2 infusions1,b
n=143 bleeding episodes
n=142 bleeding episodes
Bleeds treated with 1-2 infusions1,b
n=143 bleeding episodes
aResults shown are based on a bleed assessment by either the patient (for home treatment) or the study investigator (for treatment under medical supervision). Bleeds were assessed using a 4-point scale of excellent, good, moderate, or poor.
bResults shown are from the on-demand arm of the adolescent/adult trial, in which 15 previously treated adolescent/adult subjects were treated for on-demand bleeds. In 14 subjects, there were a total of 143 bleeding episodes. In 1 subject, no bleeding episode data were recorded.
REBINYN® TRIAL PROGRAM
Considering Rebinyn® for your patients with hemophilia B? Get a 1-month trial prescription for qualifying patients.c
To learn more about our trial prescription program, please call 1-844-NOVO-SEC (1-844-668-6732) to speak with a NovoSecure™ Specialist.
cPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
REBINYN® TRIAL PROGRAM
Considering Rebinyn® for your patients with hemophilia B? Get a 1-month trial prescription for qualifying patients.c
To learn more about our trial prescription program, please call 1-844-NOVO-SEC (1-844-668-6732) to speak with a NovoSecure™ Specialist.
cPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
HIGH FACTOR ACTIVITY
Studies show Rebinyn® elevates factor levels.1
SIMPLIFIED DOSING
Fixed dosing for all patients means no calculating desired factor IX activity levels.1
HIGH FACTOR ACTIVITY
Studies show Rebinyn® elevates factor levels.1
SIMPLIFIED DOSING
Fixed dosing for all patients means no calculating desired factor IX activity levels.1
REGISTER TO GET THE LATEST UPDATES ON REBINYN®
